Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Level 5 - mechanism / opinion, no new human data
Preclinical animal study without human data
PubMed 12711835 · doi:10.1159/000069533
What was done
Researchers evaluated the effect of oral quercetin (25–100 mg/kg p.o.) alone and combined with a subthreshold dose of L-dopa plus carbidopa in rat models of catalepsy. Catalepsy was induced via perphenazine (5 mg/kg i.p.) or reserpine (2.5 mg/kg i.p.) plus alpha-methyl-P-tyrosine (200 mg/kg i.p.) and measured using the bar test. Further drug interaction tests paired a threshold dose of quercetin with the COMT inhibitor OR-486 (10 mg/kg p.o.), the MAO-B inhibitor selegiline (5 mg/kg i.p.), or adenosine (100 mg/kg i.p.).
What was found
The abstract reports directional findings without numeric values or statistical measures. Quercetin (25–100 mg/kg) dose-dependently reversed catalepsy induced by both perphenazine and reserpine. Combining quercetin with subthreshold L-dopa/carbidopa potentiated anticataleptic effects. Pretreatment with OR-486 or selegiline potentiated the effect of threshold quercetin doses, whereas adenosine partially reversed quercetin's protective effect against perphenazine-induced catalepsy.
Why it matters
The findings provide preclinical evidence that quercetin may act as an adjunct to L-dopa therapy by enhancing dopaminergic signaling, possibly through COMT and MAO inhibition.
Limits
The study was performed exclusively in acute rodent catalepsy models, which do not fully replicate human Parkinson's disease pathophysiology. The abstract does not report animal sample sizes, exact effect magnitudes, or variance. Direct enzymatic assays measuring COMT/MAO inhibition in brain tissue were not reported in the abstract.
Cited by
- supports Quercetin, resveratrol, and curcumin slow down the metabolic breakdown of neurotransmitters, including adrenaline.